Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03000179 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03000179 is a Phase 2 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT03000179, a Phase 2 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with advanced or metastatic adenocarcinoma of the small intestine.
Interventions
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-03-03 |
| Est. Completion | 2021-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03000179
The ClinicalTrials.gov registry entry for NCT03000179 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avelumab is the first listed.
NCT03000179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03000179 about?
NCT03000179 is a clinical study titled "Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma". This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with advanced or metastatic adenocarcinoma of the small intestine.
What is the current status of trial NCT03000179?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2017-03-03. Estimated completion is 2021-08-03.
What interventions are being tested in trial NCT03000179?
The interventions under investigation include: Avelumab (DRUG).
Who is sponsoring clinical trial NCT03000179?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.